The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy
CANCER BIOMARKERS, vol.18, no.4, pp.441-449, 2017 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 18 Issue: 4
- Publication Date: 2017
- Doi Number: 10.3233/cbm-161507
- Journal Name: CANCER BIOMARKERS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.441-449
- Keywords: Breast cancer, serum FGF 21, glucose metabolism, lipid metabolism, tamoxifen, aromatase inhibitors
- Dokuz Eylül University Affiliated: Yes
Abstract
BACKGROUND: In early breast cancer patients, the effects of hormonal therapy (tamoxifen and aromatase inhibitors) on plasma fibroblast growth factor 21 (FGF-21), lipid levels and body composition have not yet been investigated. Therefore, we aimed to analyze the relationship between FGF-21 and body composition as well as the effects of tamoxifen and aromatase inhibitors on plasma lipid levels, FGF-21, and body composition.